Compare Quest Diagnostics Inc (DGX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Procter & Gamble Co — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.23B), while Procter & Gamble Co trades at $144.67 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 13× Quest Diagnostics Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| DGX | PG | |
|---|---|---|
Market Cap | $26.23B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $167.18 |
52-Week Low | $173.49 | $138.10 |
Enterprise Value | $31.99B | $366.23B |
Dividend Yield | 1.45% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.
The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.
Procter & Gamble (PG) trades at $146.38, up 0.42% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 18.44% and consistent earnings beats. The company maintains robust cash flow from operations of $17.82B in 2025 and a dividend track record, with a recent partnership with the WNBA signaling strategic brand expansion. Valuation ratios like P/E of 22.12 and P/S of 4.08 reflect a premium to peers amid modest revenue growth.
PG offers stability with high profitability and dividend reliability, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical indicators suggest caution. Key risks include economic sensitivity and competitive pressures, while institutional holdings show mixed sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
